Why Should I Vote On BetterDistricts?

Polling is a powerful tool to help our elected officials determine how they should vote.

Standard polling methods don't give you the control that you deserve. With BetterDistricts you can show your representative exactly how strongly a bill is supported in your community.

Send a clear signal on how you want your government to work.

 

S. 3420 - Accountability in Opioid Advertising Act

Introduced: 2018-09-06
Bill Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
 
Summary Not Available

Full Text


115th CONGRESS
2d Session
S. 3420


    To require the Food and Drug Administration to prioritize the promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment, in considering whether promotional materials are false or misleading.


IN THE SENATE OF THE UNITED STATES

September 6, 2018

    Ms. Harris (for herself and Mr. Gardner) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions


A BILL

    To require the Food and Drug Administration to prioritize the promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment, in considering whether promotional materials are false or misleading.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Accountability in Opioid Advertising Act”.

SEC. 2. Promotional materials for drugs.

In enforcing section 303(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333(g)) and otherwise ensuring that advertising and other promotional materials for drugs approved under section 505 of such Act (21 U.S.C. 355), including pursuant to section 503C of such Act (21 U.S.C. 353c), are not false or misleading, the Secretary of Health and Human Services shall give priority consideration to advertising and other promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment.


Relevant News Stories And Blog Posts

Title Worth Reading

Vote on S. 3420

 

Activity in last 30 days